Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
The projected business potential is around US$ 1 million in the first year
The projected business potential is around US$ 1 million in the first year
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Subscribe To Our Newsletter & Stay Updated